Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 2
Submit an article Journal homepage
787
Views
0
CrossRef citations to date
0
Altmetric
Rotavirus

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

Zhi-Wei Wua Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of ChinaView further author information
,
Fei Jina Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of ChinaView further author information
,
Qing-Liang Lib National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Jia-Mei Gaoc National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Hai-Song Zhoud Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of ChinaView further author information
,
Kai Duanb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Zhao Gaoa Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of ChinaView further author information
,
Yan Liuc National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Zhi-Yong Haod Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of ChinaView further author information
,
Wei Chenb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Yue-Yue Liuc National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Ge-Lin Xub National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Biao Yangb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Ben Dongb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Jiu-Wei Zhangb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaView further author information
,
Yu-Liang Zhaoa Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Xiao-Ming Yangb National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2263228 | Received 01 Jun 2023, Accepted 22 Sep 2023, Published online: 16 Oct 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.